QuanDx Company

QuanDx develops life science reagents and molecular diagnostic kits for applications in various diseases.
QuanDx Inc. was founded in September 2010 in New York City, NY, USA. In Jan., 2013, QuanDx moved to Bay area of San Francisco, California, the heart of biotech industry. QuanDx’ vision is to develop and commercialize innovative and unique research / clinical diagnostic assays based on proprietary technology for use in clinical and research laboratories worldwide.
Our patented technology is based on innovative Yin-Yang Probes which offer multiple benefits in the design and function of molecular based assays.
The first commercial product lines will comprise of Q-Fusion leukemia screening kits, AML/ALL leukemia screening kits, BCR-ABL P210/P190 One-tube Quant kits. The ability to detect cancer specific fusion genes is important not only in cancer research, but also increasingly in clinical settings to ensure that correct diagnosis is made and the optimal personalised treatment is chosen. It is the objective of QuanDx to offer a simpler and cost-effective solution for the detection of these important fusion genes.

Investors

Founded Date: 2010
Headquarters: Menlo Park
Technology: Personalized Diagnostics
Employee Number: 1-10
Industry: Precision Medicine
Number Of Exists: N/A
Funding Status: undisclosed
Investor Type: N/A
Investment Stage: N/A
Register and Claim Ownership